
Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Physical Activity, Vaccination May Protect Against Long COVID
2
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
3
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
4
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
5